A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment

Journal of Clinical Pharmacology

Volumn 46, Issue 1, 2006, Pages 29-36

  Bramson, Candace ^a   Ouellet, Daniele ^a   Roman, Doina ^a   Randinitis, Edward ^a   Gardner, Mark J ^a  

^a PFIZER INC   (United States)

Author keywords

Hepatic impairment; Lasofoxifene; Osteoporosis; Pharmacokinetics

Indexed keywords

LASOFOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ACCIDENTAL INJURY; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONJUGATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; FEMALE; HEADACHE; HUMAN; LIVER INJURY; LYMPHADENOPATHY; MALE; NAUSEA; OSTEOPOROSIS; SINGLE DRUG DOSE; SOMNOLENCE;

ADMINISTRATION, ORAL; ADULT; FEMALE; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES;

EID: 29644437590     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270005283278     Document Type: Article

References (22)

1. Kameda T, Mano H, Yuasa T, et al. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med. 1997;186:489-495.
2. Riggs BL, Khosla S, Melton LJ III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13:763-773.
3. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med. 2003;349:523-534.
4. Albertazzi P, Purdie DW. Oestrogen and selective oestrogen receptor modulators (SERMs): current roles in the prevention and treatment of osteoporosis. Best Pract Res Clin Rheumatol. 2001;15:451-468.
5. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337: 1641-1647.
6. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int. 2003;14:814-822.
7. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab. 2000;85:2197-2202.
8. Bolognese M, Weiss SR, Ettinger MP, Moffett AH, Lee A. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM) for the prevention of bone loss in postmenopausal women. Osteoporos Int. 2004;15(suppl 1):S11.
9. Ettinger M, Schwartz E, Emkey R, et al. Lasofoxifene: a next generation selective estrogen receptor modulator (SERM), in the prevention of bone loss in postmenopausal women. Poster presented at: ENDO 2004; June 16-19, 2004; New Orleans, La. Abstract S35-2.
10. Ke HZ, Paralkar VM, Grasser WA, et al. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 1998;139:2068-2076.
11. Rosati RI, Da Silva Jardine P, Cameron KO, et al. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem. 1998;41:2928-2931.
12. Ke HZ, Brown TA, Thompson DD. Lasofoxifene (CP-336,156), a novel selective estrogen receptor modulator, in preclinical studies. J Amer Aging Assoc. 2002;25:87-100.
13. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology. 2004;145:1996-2005.
14. Scharf S, Christophidis N. Relevance of pharmacokinetics and pharmacodynamics. Med J Aust. 1993;158:395-402.
15. Johnson KA, Gardner MJ, Prakash C. In vivo and in vitro metabolism of a next-generation selective estrogen receptor modulator, lasofoxifene, in humans. Drug Metab Rev. 2004;36(suppl 1):246.
16. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. 2002. National Osteoporosis Foundation Web site. Available at: www.nof.org/ advocacy/prevalence/. Accessed February 21, 2005.
17. International Osteoporosis Foundation. The Facts About Osteoporosis and Its Impact. International Osteoporosis Web site. Available at: http://www.osteofound.org/press_centre/fact_sheet.html. Accessed April 21, 2004.
18. Anttila M, Laakso S, Nylanden P, Sotaniemi EA. Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function. Clin Pharmacol Ther. 1995;57:628-635.
19. Taras TL, Wurz GT, Linares GR, DeGregorio MW. Clinical pharmacokinetics of toremifene. Clin Pharmacokinet. 2000;39:327-334.
20. Kohler P, Hamm JT, Wiebe VJ, DeGregorio MW, Shemano I, Tormey DC. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer. Breast Cancer Res Treat. 1990;16(suppl 1):S19-S26.
21. Evista [package insert]. Indianapolis, Ind: Eli Lilly and Co; 1997, 2003.
22. Hochner-Celnikier D. Pharmacokinetics of raloxifene and its clinical application. Eur J Obstet Gynecol Reprod Bio. 1999;85:23-29.